Pharmacologic Treatment of PTSD in Sexually Abused Children - Full Text View

Sponsor:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00078767

Purpose

This study will evaluate the benefit of adding sertraline (Zoloft®) to trauma-focused Cognitive Behavioral Therapy (TF-CBT) for sexually abused children who have Posttraumatic Stress Disorder (PTSD).

Condition	Intervention	Phase
Stress Disorders, Post-Traumatic Child Abuse, Sexual	Drug: Trauma-focused Cognitive Behavioral Therapy plus Sertraline Drug: Trauma-focused Cognitive Behavioral Therapy plus Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Child Sexual Abuse Injuries Post-Traumatic Stress Disorder Wounds

Drug Information available for: Sertraline hydrochloride Sertraline

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:	60
Study Start Date:	April 2001
Study Completion Date:	March 2006
Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Detailed Description:

Adult research has demonstrated the efficacy of selective serotonin reuptake inhibitors (SSRIs) in decreasing Posttraumatic Stress Disorder (PTSD) symptoms; to date the SSRIs are the only medication class with demonstrated efficacy in treating all three PTSD symptom clusters (reexperiencing, avoidance, and hyperarousal). No studies have evaluated the impact of SSRIs on PTSD symptoms in children or adolescents. Trauma-focused CBT has been shown in several studies to be efficacious in decreasing PTSD symptoms in sexually abused children and adolescents. Many children and youth with PTSD are currently prescribed SSRIs and other medications. This study will evaluate whether adding the SSRI sertraline provides additional benefits over TF-CBT treatment for sexually abused children and adolescents with PTSD. If adequate numbers of children with comorbid PTSD and depressive and/or anxiety disorders are included, it may also be possible to evaluate whether any benefit of adding sertraline is restricted to those children with comorbid disorders.

Eligibility

Ages Eligible for Study:	10 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Children and adolescents ages 10-18 years old who have PTSD related to sexual abuse which has been independently verified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00078767

Locations

United States, Pennsylvania
Allegheny General Hospital Center for Traumatic Stress in Children and Adolescents
Pittsburgh, Pennsylvania, United States, 15212

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

Additional Information:

National Child Traumatic Stress Network This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	K02 MH01938, DDTR BC-CB
Study First Received:	March 5, 2004
Last Updated:	February 12, 2008
ClinicalTrials.gov Identifier:	NCT00078767 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

PTSD
Depression
Anxiety

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Stress Disorders, Traumatic
Pharmacologic Actions

Serotonin Agents
Anxiety Disorders
Mental Disorders
Therapeutic Uses
Stress Disorders, Post-Traumatic
Sertraline
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 09, 2009